Paul Mueller's Q3 earnings surge y/y on industrial equipment demand and improved margins, but declining cash flows and a softer backlog raise concerns.
Paul Mueller's Q2 revenues jump 29% y/y, but lower margins weigh on earnings as strong pharmaceutical demand and a healthy backlog support the results.
Discover why Zacks, the first on Wall Street to initiate coverage, rates MUEL as "Neutral." Explore how Paul Mueller's surging backlog and pharma-driven growth are reshaping its revenue outlook amid key execution risks.